Search

Showing total 2 results
Start Over Topic humans Topic surgery Journal journal of cancer research and clinical oncology Publisher springer-verlag
2 results

1. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis

Author

L. Di Lauro, A. Vaccaro, M.A. Giampaolo, Lucia Mentuccia, Maria Agnese Fabbri, Luca Moscetti, F. Ciancola, Patrizia Vici, L. Pizzuti, Isabella Sperduti, Teresa Gamucci, and Flavia Longo

Subjects
Oncology, Adult, Risk, Cancer Research, medicine.medical_specialty, Receptor, ErbB-2, medicine.medical_treatment, Breast Neoplasms, Recurrence risk, Young Adult, Breast cancer, Small breast cancer, Recurrence, Internal medicine, medicine, Humans, Young adult, Prognostic biological factors, Survival analysis, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Original Paper, Hematology, business.industry, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Prognosis, Survival Analysis, Surgery, Node negative, Receptors, Estrogen, Node-negative, Female, Neoplasm Grading, business, Receptors, Progesterone, Adjuvant
Abstract

Purpose Recurrences and deaths are known to occur, even if less frequently, in small, node-negative breast cancer patients, and decision on adjuvant treatments remains controversial. In the present analysis, we evaluate recurrence risk in patients with pT1 a, b, c, node-negative, breast cancer, accordingly with some prognostic biological factors. Methods We retrospectively evaluated 900 node-negative patients (pT1a, b, c) surgery treated between 2000 and 2009 in four Italian oncologic centers. We defined 3 different cohorts: ER positive (ER+); Her-2 positive (Her-2+); and triple negative (TN). Results pT1a was seen in 7.6% of patients, 37.7 % pT1b, 54.8 % pT1c. Concerning the 3 different cohorts, 58.2 % were ER+; 10.8 % were Her-2+; 8.2 % were TN. Overall, chemotherapy was given to 3.0 %, 27.2 %, 69.8 % of pT1a, b, c, respectively, and to 22.7 %, 58.8 %, 68.9 % of ER+, Her-2+, TN subgroups. At a median follow-up of 67 months, 5-year DFS was 96.3 %, 89.2 %, 89.4 % in pT1a, b, c, respectively (100 %, 93.6 %, 89.8 % in ER+; 100 %, 78.7 %, 85.0 % in Her-2+; 100 %, 76.8 %, 85.2 % in TN) (p = ns). At multivariate analysis, histologic grade and Ki-67 resulted independent prognostic factors. Overall, 5-year OS was 98 %, without differences among pT1a, b, c, or among the 3 cohorts. Conclusions Overall, 5-year DFS was very favorable in this series of small, node-negative breast cancers, but Her-2+ and TN cohorts have a higher recurrence rate than ER+ cohort (p

Published
2013

2. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

Author

Jim Cassidy, Fairooz F. Kabbinavar, Ulrich-Peter Rohr, Bruce J. Giantonio, Herbert Hurwitz, and Leonard B. Saltz

Subjects
Oncology, Male, Cancer Research, genetic structures, Colorectal cancer, medicine.medical_treatment, Angiogenesis Inhibitors, Metastasis, Medicine & Public Health, Neoplasm Metastasis, Randomized Controlled Trials as Topic, Hematology, Metastatic colorectal cancer, Age Factors, Antibodies, Monoclonal, General Medicine, Middle Aged, Bevacizumab, Female, Colorectal Neoplasms, medicine.drug, Adult, medicine.medical_specialty, Randomization, Adolescent, Antibodies, Monoclonal, Humanized, Pooled analysis, Internal medicine, Internal Medicine, medicine, Older patients, Chemotherapy, Humans, Aged, Retrospective Studies, Original Paper, business.industry, Cancer, Retrospective cohort study, medicine.disease, eye diseases, digestive system diseases, Surgery, sense organs, business
Abstract

Background Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy for patients with metastatic colorectal cancer (mCRC). The relative benefit of bevacizumab in older patients has not been widely studied and is of interest. Patients and methods This retrospective analysis used data from three first-line randomized controlled studies and one second-line randomized controlled study of bevacizumab plus chemotherapy in medically fit (Eastern Cooperative Oncology Group performance status 0 or 1) patients with mCRC. Overall survival (OS) and on-treatment progression-free survival (PFS) were assessed in patients aged

Published
2009